Key Inclusion Criteria:

          -  Confirmed diagnosis of HCC by histological examination or by non-invasive criteria
             according to European Association for the Study of the Liver (EASL) or American
             Association for the Study of Liver Disease (AASLD) guidelines (Part 1, 2 and 3).

          -  For Part 1 and 2, the patient has unresectable disease and has been previously treated
             with sorafenib, has declined treatment with sorafenib, or does not have access to
             sorafenib.

          -  For Part 3, the patient has not received prior treatment with a TKI.

          -  Child-Pugh class A with no clinically apparent ascites

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  For Part 1, willing to provide archived tumor tissue (if available) and willing to
             undergo pre- and on-treatment tumor biopsy (if considered safe and medically feasible
             by the treating investigator)

          -  For Part 2 and 3, all patients must have an FGF19 IHC result available. Only FGF19
             IHC+ HCC patients will be eligible for Part 3.

        Key Exclusion Criteria:

          -  Central nervous system metastases

          -  Platelet count <75,000/mL

          -  Absolute neutrophil count <1000/mL

          -  Hemoglobin <8 g/dL

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x the upper limit
             of normal (ULN)

          -  Total bilirubin >2.5 mg/dL

          -  International normalized ratio (INR) >2.3 or prothrombin time (PT) >6 seconds above
             control

          -  Estimated (Cockroft-Gault formula) or measured creatinine clearance <40 mL/min